Session 01 · 60-minute design target
Breathlessness With a Preserved EF
Select a defensible next diagnostic step when symptoms and resting findings do not agree.
Review presentation →Expanded October 16 edition: Three full case modules · Current upload and grant materials
National HFpEF program · 2027 proposal
From the first symptom
to coordinated care.
Three women. Three clinical conversations. A program built to change the next decision.
Developed review edition. Live events are proposed; registration, faculty and credit are not yet confirmed.
3Interactive virtual case conferences
1Enduring companion activity
60 daysPlanned competence follow-up
The clinical arc
Recognize. Confirm. Keep the plan working.
Each session moves from an uncertain decision to an evidence-based next step, with faculty discussion and realistic case questions.
Session 02 · 60-minute design target
What Changes After HFpEF Is Confirmed?
Select an evidence-based treatment discussion and monitoring plan without overstating trial or label claims.
Review presentation →
Session 03 · 60-minute design target
Keeping the Plan Working
Respond appropriately to medication-related warning symptoms and complete a named monitoring and follow-up handoff.
Review presentation →A measured need.
A defined educational response.
Historical US registry data found SGLT2-inhibitor use reached only 12.8% in the combined HFmrEF/HFpEF group by Q2 2023. A selected diagnostic study also found unrecognized HFpEF among people with obesity and dyspnea. The program addresses diagnostic reasoning, treatment selection and safe implementation; these studies do not establish today’s rate or predict this program’s results.
Sources: El Rafei et al. US ambulatory HF SGLT2 prescribing. JAMA Cardiology 2025., Kosyakovsky et al. Unrecognized HFpEF in obesity and dyspnea. 2024.
Reviewer area
The national-program package
$179,000 prospective planning estimate. All rates and reach targets require quotes and review. Existing development is contributed at no requested charge. This replaces the earlier HF single-course estimate; it is not an additional overlapping request.
Priority route: Boehringer Ingelheim’s October 2026 HF IME call for 2027 live/virtual education. Saved RFP deadline: November 3, 2026. Confirm the current deadline, applicant eligibility and enduring-companion eligibility in the grant portal before submission.
- Application narratives, faculty scopes and submission assembly
- Pilot, learner-preference and release-validation materials
- Read the full independent education proposal · PDF
- Review the itemized budget and scope · Editable CSV · PDF
- Review the outcomes protocol · PDF
- 27 baseline, post-case and 60-day retention items
- Faculty and partner commitments tracker
- Submission checklist and target dates
- Provider and myCME scope brief
- Shared-funding allocation ledger
- Download the national-program reviewer package
What makes it submission-ready?
The curriculum, assessments, facilitator manuscripts, draft outcomes protocol and cost model are available. The remaining commitments are an eligible applicant, named faculty, activity-specific provider/distribution quotes, accepted reach and a final budget. Clinical approval, pilot timing, real-device/accessibility review and secure certificate configuration remain release requirements.
The working activity retains the common HEART RESERVE certificate design and browser-local noncredit completion record. No grant application has been submitted or award achieved.
60-day import and analysis instructions · Activity/item mapping · Nine reserved enduring follow-up items